Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial

Federica Cappuccini, Richard Bryant, Emily Pollock, Lucy Carter, Clare Verrill, Julianne Hollidge, Ian Poulton, Megan Baker, Celia Mitton, Andrea Baines, Armin Meier, Guenter Schmidt, Richard Harrop, Andrew Protheroe, Ruth MacPherson, Steven Kennish, Susan Morgan, Selena Vigano, Pedro Romero, Thomas Evans, James W.F. Catto, Freddie Hamdy, Adrian V.S. Hill, Irina Redchenko
doi: https://doi.org/10.1101/2020.03.05.20031500

Data Availability

The data that support the findings of this study are available from the corresponding author, IR, upon reasonable request.

Back to top
Posted March 09, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial
Federica Cappuccini, Richard Bryant, Emily Pollock, Lucy Carter, Clare Verrill, Julianne Hollidge, Ian Poulton, Megan Baker, Celia Mitton, Andrea Baines, Armin Meier, Guenter Schmidt, Richard Harrop, Andrew Protheroe, Ruth MacPherson, Steven Kennish, Susan Morgan, Selena Vigano, Pedro Romero, Thomas Evans, James W.F. Catto, Freddie Hamdy, Adrian V.S. Hill, Irina Redchenko
medRxiv 2020.03.05.20031500; doi: https://doi.org/10.1101/2020.03.05.20031500
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area